BIRMINGHAM, Ala., April 05, 2018 -- On Thursday, the Honorable David R. Proctor granted Plaintiffs’ Motion for Partial Summary Judgment and ordered that agreements among Blue Cross Blue Shield entities across the country to allocate markets and limit competition will be reviewed as per se violations of the Sherman Act. Judge Proctor concluded: “Plaintiffs have presented evidence of an aggregation of competitive restraints…which, considered together, constitute a per se violation of the Sherman Act.”
The litigation, originally filed in 2013, alleges that over 30 Blue Cross Blue Shield health insurance companies have entered into agreements not to compete with each other for health insurance customers, both by allocating the markets in which they sell health insurance and capping the amount of unbranded health insurance they offer. Hausfeld represents a class of subscribers of health insurance alleging that these rules have artificially inflated premiums and decreased consumer choice in the market for health insurance.
In 2017, the parties briefed whether the challenged rules should be reviewed under a per se standard that would prevent Defendants from claiming procompetitive benefits for their agreements. Upon review of an extensive discovery record, including internal documents and Defendant testimony admitting the anticompetitive nature and purpose of the rules, Judge Proctor issued a 59-page decision agreeing with Plaintiffs that the rules must be accorded per se treatment.
“Our case alleges that, for decades, the Blue Cross Blue Shield system has operated as an illegal association of competitors trying to suppress competition in order to inflate their own profits at the expense of their customers,” said Hausfeld Chairman and Co-Lead Counsel Michael D. Hausfeld. “We look forward to taking our case to trial and achieving a nationwide injunction to stop these practices once and for all.”
“Thursday’s order is a victory for the millions of subscribers of Blue Cross Blue Shield healthcare,” said Megan Jones, Hausfeld Partner and Plaintiffs’ Steering Committee member. “We are proud to have taken a step closer to opening up the market for health insurance to true competition, to the benefit of all Americans. We want there to be more competition for everything from chemotherapy to casts for subscribers in the U.S., and Thursday’s decision advances that goal.”
Hausfeld attorneys working on this case are Michael Hausfeld, Megan Jones, Michael Lehmann, Scott Martin, Arthur Bailey Jr., Swathi Bojedla, and Braden Beard. The case is In re BCBS Antitrust Litigation, Case No. 13-cv-20000-RDP (N.D. Ala.).
For further information or to arrange interviews, please contact:
Kelly Nguyen
Hausfeld LLP
[email protected]
(415) 744-2968
About Hausfeld:
Hausfeld is a leading global law firm with offices in Berlin, Boston, Brussels, Dusseldorf, London, New York, Philadelphia, San Francisco, and Washington, DC. The firm has a broad range of complex litigation expertise, particularly in antitrust/competition, financial services, sports and entertainment, environmental, mass torts, consumer protection, and human rights matters, often with an international dimension. Hausfeld aims to achieve the best possible results for clients through its practical and commercial approach, avoiding litigation where feasible, yet litigating robustly when necessary. Hausfeld’s extensive experience with alternative and innovative fee models offers clients a diverse menu of engagement options and maximum flexibility in terms of managing their cost exposure.
Hausfeld is the only claimants firm to be ranked by the Legal 500 and Chambers & Partners as a top tier firm in private enforcement of antitrust/competition law in both the United States and the United Kingdom. For more information about the firm, including recent trial victories and landmark settlements, please visit: www.hausfeld.com.


Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
Apple Restores Telegram to App Store After Content Policy Violation
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 



